Fig. 5

SB203580 alleviated combined LAP and DOX exposure-induced cardiotoxicity. (A-D) Representative bright field images (A) and quantification of ventricular cross-sectional areas (B), the percent fractional shortening (FS) (C), and heart rates (D) of embryos in the LAP and DOX combination-induced cardiotoxicity model that were treated with small molecular inhibitors of oxidative stress or the MAPK signaling pathway. The ventricle borders are outlined by dashed white lines.N=10; one-way ANOVA. SB, SB203580; AST, Astaxanthin; PL, Piperlongumine; PD, PD0325901. (E-G) Western blotting (E) and quantification of p-p38 normalized to total p38 and p-Jnk normalized to total Jnk (G) in the combined LAP and DOX exposure-induced cardiotoxicity model that was treated with 5 μM SB203580 or the DMSO control. N=3 biological replicates, one-way ANOVA. (H-J) Quantification of ROS-related indices, including CAT (H), SOD (I) and MDA (J), in the LAP and DOX combination-induced cardiotoxicity model that was treated with 5 μM SB203580 or the DMSO control. N=4, one-way ANOVA; *P<0.05, **P<0.01, ***P<0.001, ns, not significant.